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Authors’ response 
 
We thank Drs Wolkewitz, Schumacher, Jones, Del Mar, Hama, Antes and Meerpohl for their 
comments 1-3 and address the key issues raised in a single response. 
 
Potential datasets for the IPD analysis were identified via a systematic review4 of published papers 
investigating the association between neuraminidase inhibitor (NAI) antiviral use and public health 
outcomes in hospitalised A(H1N1)pdm09 patients. This included quality assessment of studies using 
the Newcastle Ottawa Scale (NOS); median score 6 (range: 4-9). Studies were scored lower primarily 
because of failure to adjust for confounders. 
 
To ensure that we included as many datasets as possible in the subsequent IPD analysis, we 
contacted authors of any publications (including letters) suggesting that they may have access to 
pandemic patient surveillance datasets including data on NAI antiviral use and patient outcomes. 
Our current publication5 is part of a broader programme of study 6 and only reports on one of the 
primary outcomes of interest, namely mortality.  
 
Of the 44 published studies included in our earlier systematic review4, we were unable to obtain 37 
datasets that included data on NAI antiviral use and mortality (median NOS score 6; range 4-9). Of 
these, 9 reported results significantly in favour of NAI antiviral treatment, none reported results 
significantly against NAI antiviral treatment and 28 did not find significant associations between 
treatment and mortality. The majority of our data were from unpublished surveillance studies that 
met our minimum dataset criteria and were then standardised according to an agreed protocol5. 
Some data contributors provided all their raw unprocessed data thus explaining why we have some 
missing values for NAI antiviral use. Figure 15 shows missing data on mortality and NAI antiviral use 
for transparency. We are unable to comment on unpublished datasets that are not included in our 
analysis or the extent to which these could bias our findings; this is clearly acknowledged in our 
paper5. 
 
Industry-sponsored trials involving A(H1N1)pdm09 patients would have met our inclusion criteria. 
We actively searched trials registers and contacted both NAI manufacturers for such studies during 
the conduct of our previous systematic review 4 but no data pertaining to the pandemic virus were 
identified. 
 
With regard to the datasets included in the IPD analysis, all data contributors (co-authors) were 
asked to declare conflicts of interest including industry-sponsorship for their datasets, using the 
standard ICJME proforma. None of the datasets were declared as being industry-sponsored. A 
statement of declaration of interests can be found in the publication5. 
 
We have acknowledged in our paper that there are inherent limitations in a retrospective IPD 
analysis of observational data and our propensity score adjustment cannot completely eliminate 
selection bias or confounding by indication. Our conclusions that early NAI antiviral treatment is 
associated with a reduction in mortality are based on the results of the generalised linear mixed 
models.  
 
Jones has already queried the validity of our time-dependent analysis elsewhere7, 8 and we have 
submitted a detailed response9, 10 explaining that we have used standard methods for modelling NAI 
antiviral use as a time-dependent covariate by splitting survival time in treated patients into 
untreated and treated time to account for immortal time bias. While, the publication by Beyersmann 
et al. 11 provided mathematical proof that accounting for time-dependent exposures should diminish 
the treatment effect, it did not focus on shared frailty models (to account for clustering nature of 
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our data) or the effect of other time-dependent biases and competing risks. Therefore, it is difficult 
to predict the shift in direction of the treatment effect when shared frailty models are considered. 
 
Wolkewitz and Schumacher1 make a valid point that patients who are discharged alive from hospital 
(competing risk for death) are presumably in a better health condition than patients who remain in 
hospital and we thank them for suggesting the Fine and Gray subdistribution hazard regression 
model12.  However, accounting for all these biases in a single model with shared frailty is complex 
and standard statistical software packages cannot currently deal with them. Moreover, whether 
shared frailty models allowing for competing risks are appropriate is a controversial topic that needs 
to be resolved before they can be applied to clinical questions of such importance.   
 
The accompanying table presents results from a series of models with advantages and disadvantages 
listed for each. In addition we include the hazard ratio for being discharged alive within 30 days of 
illness onset to illustrate the potential impact of discharge as a competing risk for the outcome 
death; this suggests patients who received antivirals were more likely to be discharged. Even though 
we are unable to quantify this effect at present using a single model which accounts for all the 
complexities mentioned above, it is unlikely that accounting for the competing risk will shift the 
effect of NAI antiviral treatment on the hazard of death towards the null. 
 
 
 Comparison of findings from various models (NAI treatment at any time versus none) 
Model used (outcome) Adjusted
†
 Ratio (95% CI) 
 
Main advantages and disadvantages 
Odds ratio (in-patient death): 
generalized linear mixed model 
with study fitted as a random 
intercept 
0·81 (0·70–0·93)
1
 Accounts for competing events and 
clustering; ignores time dependency of 
exposure and outcome 
Hazard ratio (in-patient death): 
standard Cox regression model 
 
0.36 (0.32-0.41)
2
 Antiviral use modelled as a time constant 
exposure; does not take into account 
clustering or immortal time bias 
Hazard ratio (in-patient death): 
time-dependent Cox regression 
model  
 
0.53 (0.48-0.59)
2
 Antiviral use modelled as a time 
dependent exposure to account for 
immortal time bias; does not take into 
account clustering  
Hazard ratio (in-patient death):  
Cox regression shared frailty model 
0.94 (0.80-1.10)
2
 Antiviral use modelled as a time constant 
exposure; does not take into account 
immortal time bias; takes into account 
clustering  
Hazard ratio (in-patient death): 
time-dependent Cox regression 
shared frailty model 
0·51 (0·45–0·58)
1
 Antiviral use modelled as a time 
dependent exposure to account for 
immortal time bias; takes into account 
clustering 
Hazard ratio (in-patient death): 
Hazard ratio (discharge): 
time-dependent Cox regression 
shared frailty model 
0.54 (0.47-0.62)
2* 
1.09 (1.05-1.13)
2*
 
Antiviral use modelled as a time 
dependent exposure to account for 
immortal time bias; takes into account 
clustering; HR for discharge illustrates the 
potential impact of discharge as a 
competing risk for the outcome death  
† 
Adjusted for propensity score quintile and treatment with corticosteroids and antibiotics 
*A subset of the sample used for the survival analysis (99%) presented in Muthuri et al. (2014) where  dates of discharge 
were known  
1 
Findings presented in Muthuri et al. (2014); 
2 
New results from additional analyses conducted in response to Wolkewitz 
and Schumacher (2014) 
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In summary, we hope we have provided an adequate clarification on the issues raised in the 
correspondence and demonstrated how various biases and assumptions affect the results. This 
highlights the importance of a consensus in the scientific community regarding how to model shared 
frailty with competing risks and time dependent analyses to account for immortal time bias and time 
varying effects.  
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